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33 Abstract
34 Despite recent advances in male reproductive health research, there remain many elements of male 
35 (in)fertility where our understanding is incomplete. Consequently, diagnostic tools and treatments for 
36 men with sperm dysfunction, other than medically assisted reproduction, are limited. On the other 
37 hand, the gaps in our knowledge of the mechanisms which underpin sperm function have hampered 
38 the development of male non-hormonal contraceptives. 
39 The study of mature spermatozoa is inherently difficult. They are a unique and highly specialised cell 
40 type which does not actively transcribe or translate proteins and cannot be cultured for long periods 
41 of time or matured in vitro. 
42 One, large scale, approach to both increasing understanding of sperm function, and the discovery and 
43 development of compounds that can modulate sperm function, is to directly observe responses to 
44 compounds with phenotypic screening techniques. These target agnostic approaches can be 
45 developed into high-throughput screening platforms with the potential to drastically increase 
46 advances in the field.
47 Here we discuss the rationale and development of high-throughput phenotypic screening platforms 
48 for mature human spermatozoa, and the multiple potential applications these present, as well as the 
49 current limitations and leaps in our understanding and capabilities needed to overcome them. Further 
50 development and use of these technologies could lead to the identification of compounds which 
51 positively or negatively affect sperm cell motility or function, or novel platforms for toxicology or 
52 environmental chemical testing among other applications. Ultimately, each of these potential 
53 applications is also likely to increase understanding within the field of sperm biology.
54
55
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56 Introduction.
57 Recently, there have been several significant developments in male reproductive health that have not 
58 only increased our understanding of basic mechanisms but also opened exciting areas of research. 
59 One is uncovering how epigenetic modification of the paternal gamete can potentially have profound 
60 effects on the health of subsequent generations (Bodden, et al. 2020, Lismer, et al. 2021). Another is 
61 understanding how male reproductive health is increasingly viewed as a sentinel marker for somatic 
62 health issues (Choy and Eisenberg 2018, Del Giudice, et al. 2021) and, the health of subsequent 
63 offspring (Kasman, et al. 2020). However, there are two key areas where progress remains limited 
64 namely (1) the diagnosis of and non-Medically Assisted Reproduction (MAR) treatment of men with 
65 sperm dysfunction (2) development of new male contraceptives. 
66 This review outlines these two areas including discussing the driving requirement for progress. A 
67 common roadblock limiting development, namely the relatively rudimentary understanding of the 
68 underlying physiology and function of the mature spermatozoon is presented. The focus is discussing 
69 the potential uses of a High Throughput Phenotypic Screening assay of the mature human 
70 spermatozoon. This can be used as a platform technology to devise new diagnostic tools and non-MAR 
71 therapies, as a tool for the development of new targets and drugs for male contraception and to 
72 improve our underlying knowledge of the cell.
73 Background
74 Sperm dysfunction, diagnosis, and non-MAR Treatment 
75 A plethora of studies demonstrate that our understanding of the physiology of the mature human 
76 spermatozoon is quite limited and this is a significant roadblock to the development of badly needed 
77 diagnostic and therapeutic tools (Barratt, et al. 2017, Barratt, et al. 2021, De Jonge and Barratt 2019, 
78 Schlegel, et al. 2021a, b). Consider for example the development and use of sperm function assays. 
79 There is clear information that classical sperm function tests such as the generation of reactive oxygen 
80 species (ROS) and assessment of subsequent damage to the cell have significant clinical value [see 
81 reviews (Aitken & Bakos, 2021, Oehninger and Ombelet 2019)]. However, these assays have yet to be 
82 translated into robust tests that are routinely used in the clinical setting. Why? There are several 
83 reasons, but primary amongst these is our relatively low knowledgebase of the mature spermatozoon 
84 and what separates function from dysfunction at a phenotypic level within these assays. One example 
85 illustrates this - the complexities of ROS generation and the assessment/impact of ROS damage. Thirty 
86 years ago, seminal work from John Aitken and colleagues (Aitken, et al. 1991) provided clear evidence 
87 that generation of ROS in a semen sample had a negative impact on the chances of achieving an in 
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88 vivo pregnancy in 139 sub-fertile couples. A plethora of subsequent experiments unveiled the 
89 complexity of ROS generation as a ‘friend and foe’ to the spermatozoon and, the challenges of 
90 assessing subsequent damage to the cell. Consequently, developing an assay(s) that could easily 
91 reflect pathological ROS generation and damage with clear, cut-off values and reference ranges, is not 
92 simple. Suffice it to say we still do not have sufficient detailed biological knowledge to illuminate clear 
93 diagnostic assays. John Aitken succinctly summarised the reality of the situation as there being 
94 ‘rampant uncertainty’ about which assays to use (Aitken 2021). 
95 A detailed understanding of the physiology of a sperm cell is not only important for the development 
96 of diagnostic tools but also to develop rational non-MAR treatment. For example, to successfully use 
97 antioxidants for the treatment of sperm dysfunction its first necessary to demonstrate that oxidative 
98 stress is the cause of the infertility. The continual unsuccessful use of antioxidants for male infertility 
99 is testament to the fact that we have yet to solve this conundrum (Aitken 2021). 
100 Male contraception. 
101 Remarkably, there remain only two well established methods of male contraception namely 
102 vasectomy and condoms both of which have inherent disadvantages limiting global utilization. 
103 Progress in male hormonal contraception has been slow particularly considering that promising trials 
104 were published 25 years ago (World Health Organization Task Force on Methods for the Regulation of 
105 Male Fertility 1996) and currently, despite much discussion, there are no products on the horizon 
106 (Reynolds-Wright and Anderson 2019, Thirumalai and Amory 2021). Moreover, whilst there has been 
107 significant activity to elucidate potential key targets for non-hormonal contraception, high quality 
108 human targets have yet to be realized (Long, et al. 2021). Although there are possibilities for targets 
109 allowing interruption of spermatogenesis and/or manipulation of the epididymal environment, of 
110 particular concern is the scarcity of new targets in the mature human spermatozoon. 
111 As indicated, a fundamental challenge in andrology remains the paucity of knowledge of the 
112 physiological workings of the normal (and dysfunctional) spermatozoon. Although progress has been 
113 made for example using proteomics or electrophysiology, our discipline still lacks real intensity in 
114 these areas. For example, we don’t have a detailed understanding of the quantitative protein 
115 composition of the spermatozoa, including post translational modifications, and protein interactions 
116 [cf sea urchins (Trötschel, et al. 2020)]. Electrophysiological data is still limited on patient samples 
117 (Brown et al., 2019) and single cell analysis and imaging is only recently gaining traction (Kandel, et al. 
118 2020, Moscatelli, et al. 2017, Nandagiri, et al. 2021). The power of technology is impressive but uptake 
119 and overall development in the discipline of human sperm biology has been relatively slow. 
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120 High throughput phenotypic screening
121 High throughput phenotypic screening in general biology 
122 Phenotypic screening is a target agnostic approach where phenotypic responses to compounds are 
123 directly observed. Therefore, compounds that produce a desired phenotype can be identified even 
124 when knowledge of molecular targets are limited. Further, screening can be carried out to probe 
125 different phenotypes, that may have different physiological relevance. However, care must be taken 
126 that the phenotypic assay is relevant to the disease context in the patient (De Rycker, et al. 2018). To 
127 achieve this, usually it is necessary to develop screening cascades with a variety of secondary assays 
128 (Field, et al. 2017).
129 Compounds that produce phenotypic responses, or “hit” compounds can be used to identify novel 
130 targets, and/or can be modified to modulate the phenotype further. Phenotypic screening is a 
131 common approach in drug discovery (Gilbert 2013, Moffat, et al. 2017) and has been successfully used 
132 to discover several new compounds for major disorders and diseases e.g. fragile X syndrome 
133 (Kaufmann, et al. 2015), hepatitis C (Gao, et al. 2010), cryptosporidiosis (Jumani, et al. 2019, Love, et 
134 al. 2017, Love and McNamara 2021), and malaria (Antonova-Koch, et al. 2018, Baragaña, et al. 2015, 
135 Baragaña, et al. 2016).
136 In addition to identifying potential drug candidates, phenotypic screening can provide insights to 
137 improving the understanding of biology of the cells or complex model systems in normal or diseased 
138 states, by identifying novel, chemical tools (Moffat, et al. 2017). Phenotypic compound profiles can be 
139 created through the generation and analysis of complex and rich datasets that describe a multitude 
140 of cellular parameters (e.g. morphology, gene/protein expression levels), or functions (e.g. velocity). 
141 These profiles can provide a rationale for the identification of molecular targets (target deconvolution) 
142 to determine the mechanism of action of hit compounds (Chandrasekaran, et al. 2021, Hughes, et al. 
143 2021, Ziegler, et al. 2021). Whilst target deconvolution of hits can be challenging, this provides 
144 valuable information in understanding the fundamental biology of the cell, for medicinal chemistry 
145 optimisation of drug hits and leads, and the potential clinical use of a compound. 
146 As a platform for drug discovery and for furthering molecular understanding, the inherent advantages 
147 of the phenotypic screening approach are readily translatable to the human spermatozoon. Several 
148 functional and clinically relevant in vitro assays, such as sperm motility, acrosome reaction, and 
149 intracellular calcium flux assays, have the potential to form a basis for phenotypic screening assays. 
150
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151 Development of Phenotypic screening for human spermatozoa 
152 Development of a high-throughput phenotypic assay for the assessment of human sperm function 
153 brings significant technical obstacles. For example, the system must be largely automatic (require 
154 minimal labour input), requiring sophisticated robotics, and directly assess the effects of numerous 
155 (thousands) of compounds on sperm cell function within a short time. It must also be based on robust 
156 (good Z’ score) and reproducible assays, with a good signal to noise ratio and a measurable end-point. 
157 We have addressed these challenges and developed a high-throughput phenotypic platform (Figure 
158 1), to measure motility (Gruber, et al. 2020), as well as other key attributes of the human 
159 spermatozoon (Figure 2). The platform utilises a fully automated robotics platform to carry out 
160 primary screening assays in a plate-based format and resulting data analysis can be largely automated 
161 to process the large amounts of data these high-throughput screens produce. The flexibility and 
162 automation allows for multiple aspects of sperm function to be interrogated with different assays 
163 (Figure 2). This platform has been utilized to screen several libraries to demonstrate that the assay is 
164 scalable, provides consistent biological data compared to traditional sperm function assays such as 
165 CASA, and rapidly samples sufficient numbers of cells. In addition, the platform also provides the 
166 opportunity for further developments; to adapt the screening platform to other assays and purposes. 
167 For example, the addition of conditions that support capacitation, the flexibility of compound addition 
168 and incubation times (Figure 1) or the opportunity to adapt the technology to answer different 
169 questions with different physiologically relevant environments. 
170 Now that a high-throughput phenotypic assay is available what opportunities arise? We identify five 
171 areas to illustrate the potential power of this technology. Although these are presented as separate 
172 entities, they are not exhaustive or mutually exclusive and there is significant overlap such that data 
173 from one area inform another. 
174 1. Identification of compounds negatively affecting human sperm function: male contraception.
175 A premise for a phenotypic screen is to have an assay that has physiological/disease relevance. Sperm 
176 motility is ideally suited as it is easy to measure and is related to both in vivo and in vitro fertility 
177 (Tomlinson, et al. 1999). Consequently, a phenotypic assay based on sperm motility is a logical 
178 approach for the assessment for contraceptive purposes. This is our primary strategy for the 
179 identification of compounds that adversely affect sperm motility, as part of the Bill and Melinda Gates 
180 Foundation Contraceptive Program. https://gcgh.grandchallenges.org/challenge/accelerating-
181 discovery-non-hormonal-contraceptives
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182 Several different strategies can be adopted to achieve this goal. For example, the assessment of 
183 libraries enriched or specifically containing repurposing compounds such as the ReFRAME library 
184 (https://reframedb.org/; (Janes, et al. 2018). A primary advantage of this approach is that, if a 
185 compound(s) of interest is identified then it is likely to be accompanied by significant safety/clinical 
186 development data thus facilitating more rapid development and potential translational impact. 
187 Screening of repurposing libraries is a successful approach as exemplified by its use in anti-
188 cryptosporidial (Janes, et al. 2018) and anti-leishmanial drug development (Patterson and Fairlamb 
189 2019) that have led to rapid progression of compounds into clinical trials, clofazimine for 
190 cryptosporidiosis and fexinidazole for visceral leishmaniasis. 
191 A complementary strategy could include using chemogenomic libraries. These are known small 
192 molecule pharmacological agents against a broad spectrum of annotated targets/pathways. Thus, the 
193 emphasis when using these is not on generation of chemical matter as for a medicinal chemistry 
194 program but for generating information on potential targets and informing follow up on target 
195 identification (Jones and Bunnage 2017). Examples of such libraries include Sigma library of 
196 pharmacologically active compounds (LOPAC1280; www.sigmaaldrich.com), Prestwick Chemical 
197 library (www.prestwickchemical.com) both of which have been used in a large number of publications. 
198 Another approach could be the use of pharmacologically focused libraries that contain known 
199 inhibitors or chemical scaffolds for target classes such as proteins kinases (Brenk, et al. 2008, 
200 Woodland, et al. 2015). Kinases play a significant role in human sperm function and testing these 
201 libraries could be helpful in addressing their role. As it’s a phenotypic screen and the whole intact 
202 spermatozoon is being assessed, a key advantage of such annotated libraries is that not only one or 
203 several kinases are examined but the whole kinome is examined, leading to an understanding of 
204 kinases in their biologically relevant states. 
205 Following initial screening and hit identification, hits must be confirmed, usually through the re-supply 
206 of fresh chemical compound, re-testing, and subsequent testing in a variety of biological and 
207 pharmacological assays, as guided by a Target Candidate Profile. The aim of this work is to optimise 
208 the compounds to increase potency and improve physicochemical, pharmacokinetic and safety 
209 profiles. In the case of sperm, an initial important assay is to check the compounds in a mammalian 
210 cell line (counter screen), to ensure that there is a measurable selectivity window between sperm 
211 motility inhibition and general cytotoxicity. Further assays include in vitro physicochemical profiling 
212 such as solubility and metabolic stability in liver microsomes. This screening cascade would also 
213 include a series of additional assays, both cellular and animal models, to assess the biological activity 
214 of key compounds against sperm and their likely effectiveness as a contraceptive.
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215 Although the use of phenotypic screening of human sperm is still in the early stages, it potentially 
represents a disruptive technology in the arena. Several interesting preliminary compounds have been 
identified using the above approaches (Gruber, et al. 2020), and are currently generating potential 
start points for a contraceptive medicinal chemistry programme. Disulfiram is one example of an 





220 short time frame (1 hour). Although not deveopable as a male contraceptive, due to likely side-effects, 
the identification of Disulfiram indicates that compounds with robust contraceptive activity can be 
identified using this approach, for either progression into a medicinal chemistry programme or for use 




224 2. Identification of compounds positively affecting sperm motility: potential for non-MAR
225 therapy.
226 Identifying compounds that increase sperm motility (but do not adversely affect other critical aspects 
227 of sperm function) has been a key goal in clinical andrology for decades. If effective and safe, such 
228 compounds could be used in MAR treatments such as intrauterine insemination [see (Tardif, et al. 
229 2014)] where the objective would be to temporarily improve the motility of the cell so that there were 
230 a higher number of functional cells able to reach the site of fertilisation and/or interact with the egg. 
231 The compounds could be added to the sperm cells during the normal routine processing of the sample 
232 for insemination and if effective would make treatment more cost effective, less complex, and widely 
233 available as treatment became available for more patients. 
234 Whilst the screening system for examining compounds that increase motility is effectively the 
235 opposite to contraception it’s not simply a case of observing a different readout - increase vs decreases 
236 in motility. The systems need to be set up differently as the aims are diametrically opposed. For 
237 contraception purposes a fast-irreversible block of motility is the goal. For enhancement of fertility, 
238 motility would need to be relatively long lasting rather than a temporary boost and, conversely, it’s 
239 important not to overstimulate the cell to avoid metabolic exhaustion. As such the assessment time 
240 periods are considerable. Also, it is necessary to study the effects in different environments e.g. non 
241 capacitating, capacitating conditions to examine if the effect is modified or even negated as the cell is 
242 processed and moves toward the egg (Tardif, et al. 2014). Different counter screening is also necessary 
243 for example to eliminate undesired adverse outcomes on the fertilising ability of the cells such as 
244 avoiding premature stimulation of the AR. Using the phenotypic motility screening approach, in
245 preliminary data, several compound classes have been identified which warrant such further 
246 investigation  (Gruber, et al. 2021; under review and available as a pre-print).
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247 In  this case, a similar library selection strategy to identify compounds, which have a negative effect on 
248 sperm function, as in the contraceptive approach, was adopted e.g. chemogenomic and focussed 
249 libraries. However, it would be interesting to examine the repurposing of target-annotated libraries 
250 as identification of compounds in this area may facilitate a more rapid translation to the clinic, where 
251 safety data for the compound already exists or the compound is already in therapeutic use for another
252 indication. 
253 3. Improving our understanding of the functional mature spermatozoon
254 There are several areas where a phenotypic assay could potentially be utilised to improve our 
255 fundamental knowledge of the cell. For example, understanding the role of ion channels. A wealth of 
256 data suggests that these are critical for human sperm function but even the basic operation of the 
257 most widely studied channel - CatSper – remain somewhat a mystery (Brown, et al. 2019). 
258 Furthermore, we don’t have a full inventory of the functional ion channel repertoire of the human 
259 sperm plasma membrane. 
260 One approach to examine ion channel function in the human spermatozoan would be to screen 
261 against large commercially available libraries containing putative or known ion channel inhibitors. 
262 Initial experiments could assess effects on, for example, basal motility and kinematics. This would 
263 address the question of what role ion channels play in the maintenance of sperm motility. Further 
264 experiments could extend to assessing the cells incubated under capacitating and non-capacitating 
265 conditions providing important insight into the role of capacitation. Moreover, as assessment of 
266 hyperactivation is standard in CASA (Mortimer and Mortimer 2013) it is easily translatable to 
267 phenotypic screening. The importance of ion channels in maintenance and induction of 
268 hyperactivation could then be examined on a high-throughput scale including assessment of the 
269 dynamic nature of these events. 
270 An important issue in the advancement of andrology is a lack of consistency between research 
271 groups, and indeed clinics, in sperm handling techniques and in culture media composition. This 
272 may, in part, explain some of the uncertainty and conflicting literature in the field (Hernández-Silva, 
273 et al. 2020). For example, recent work elucidating the mechanistic role of albumin in activating the 
274 proton channel hHv1 and capacitation of human sperm (Zhao, et al. 2021) highlights the importance 
275 of sufficient levels of albumin in sperm culture media to fully support capacitation. Experiments 
276 carried out in media with differing levels of albumin have the potential to yield differing results due 
277 to impaired capacitation. A plate-based screening platform may also provide an approach for 
278 examining the phenotypic effects of different culture condition and media additives on the mature 
279 human sperm cell in parallel. The scale and flexibility of high-throughput platforms could also aid in 
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280 addressing other conflicting data within the field, where there is a particular need to screen large 
281 numbers of compounds/samples under consistent conditions, for example the action of endogenous 
282 steroids and plant triterpenoids on the regulation of human CatSper (Brenker, et al. 2018, 
283 Mannowetz, et al. 2017, Rehfeld 2020).
284 Understanding is not limited to investigation of the normal spermatozoon. Whilst we have not 
285 examined it, the system could be used to test well-defined cohorts of patient samples. For example, 
286 when determining effects of compounds to potentially increase motility, do all patients with isolated 
287 asthenozoospermia have the same kinetic responses? Moreover, these patients’ sample could be 
288 assessed under the same conditions (e.g. capacitation timing) determining the dynamics of individual 
289 responses.
290 4. Large scale screening of potential toxicants: environmental/occupational chemicals.
291 There is a growing body of data on the potential direct effect of environmental chemicals. Although 
292 currently this work is largely restricted to examination of outputs such as calcium (Birch, et al. 2021, 
293 Rehfeld, et al. 2020, Schiffer, et al. 2014), several small scale studies have indicated direct effects of 
294 specific environmental chemicals and mixtures on sperm motility (Grizard, et al. 2007, Pant, et al. 
295 2013, Sumner, et al. 2019). High-throughput examination of sperm motility (and other functional 
296 attributes) could provide complementary data on a larger scale and may be particularly relevant 
297 where assessing the complexities of interactions between compounds, which require quantum leaps 
298 in throughput. 
299 5. Future Method Development:
300 In addition to the assessment of motility we have developed a phenotypic screen for the AR that uses 
301 lectins well established in sperm physiology (Mortimer, et al. 1987). Importantly, we have multiplexed 
302 the motility and AR phenotypic assays so that, if required, in one well we can report the activity of a 
303 compound on two key aspects of sperm function (Gruber, et al. 2020). 
304 The development of increasing numbers of in vitro technologies for cell-based assays further 
305 augments the potential benefits of phenotypic screening. In essence, having established a 
306 fundamental platform, if a robust and functionally appropriate assay is available, it could be 
307 miniaturized and adapted for use in the phenotypic screen. In sperm biology this could range from 
308 examination of tyrosine phosphorylation (Matamoros-Volante, et al. 2018) to assessment of 
309 membrane potential with the latter recently associated with fertilising capacity (Baro Graf, et al. 2019, 
310 Brown, et al. 2016, Molina, et al. 2019). 
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311 A physiologically and clinically relevant phenotypic assay is a cornerstone of phenotypic screening. 
312 Whist in vitro assessment of sperm motility is used clinically and has both diagnostic and predictive 
313 value [e.g. (Tomlinson, et al. 1999)] it is assessed in non-viscous media. In contrast, sperm spend their 
314 functional life in more viscoelastic environments in the female tract, hence adapting and developing 
315 in vitro tests to make them more physiologic may be helpful. For example, adaption of the viscous 
316 media penetration assay (Kremer test) that is used as a simple, reliable but very low-throughput 
317 method to demonstrate the effect of compounds on sperm motility would be a valid phenotype 
318 (McBrinn, et al. 2019, Williams, et al. 2015, Yuan, et al. 2020).
319 Whilst the focus of this review is on the human spermatozoon, the same technology can also be 
320 adapted, and fine-tuned for use on animal spermatozoa. For example, we have modified the high-
321 throughput phenotypic motility screening assay so it can be used on conventional and sex sorted 
322 cryopreserved bovine spermatozoa (McBrinn unpublished) opening the technology to research in 
323 animal reproduction. 
324 Limitations of phenotypic screening
325 High-throughput phenotypic screening of the human spermatozoon requires expensive technology 
326 that is not routinely available within academic settings. Moreover, any phenotypic assay is by 
327 necessity a compromise between the need to rapidly obtain information on large numbers of 
328 compounds and having an assay that represents the functions of the cell. For example, media 
329 conditions can either be non-capacitating or support capacitation and cells must be prepared and 
330 washed for dispensing rather than examining compound exposure in the presence of seminal plasma. 
331 Therefore secondary, lower-throughput, assays are required to fully examine the effects of hit 
332 compounds. 
333 Moreover, whilst compound identification and effect are the remit of phenotypic screening it’s only a 
334 platform for further study. Identification of the target (target deconvolution) and detailed 
335 mechanisms of action (MOA) studies are usually required, and, in some cases, these can be difficult to 
336 achieve. For example, McBrinn et al. (2019) and colleagues describe the hurdles in examining MOA of 
337 a well-known phosphodiesterase inhibitor of sperm function - Trequinsin. In some arenas, despite 
338 numerous years of research, the MOA of compounds can be poorly understood even when these are 
339 drugs commonly used to treat disease 
340 Fortunately, along with the complex screening technologies and physicochemical assessments 
341 available with high-throughput screening technologies and drug discovery, within andrology further 
342 functional assays are available to be adapted for both hit confirmation and targe deconvolution. For 
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343 example, adapted viscous media penetration assays can be used to examine the effects on prepared 
344 cells or raw semen, and sperm cells subsequent ability to penetrate a physiologically relevant 
345 viscoelastic medium (McBrinn, et al. 2019, Tardif, et al. 2014).
346 For further method development, some biological challenges remain that limit adaptations of 
347 phenotypic screening of the human spermatozoon. For AR, while we can assess the effects of 
348 compounds on their potential to induce AR, for contraceptive purposes, it would be interesting to see 
349 if compounds were able to block physiological induction of AR. However, to achieve this we would 
350 need to have a single robust and reliable physiological agonist, which is unfortunately not yet 
351 available. 
352 As high-throughput systems aim to automate as much of the workflow as possible, the technology 
353 has largely been utilised with adherent cell lines. These, for the most part, can be cultured over 
354 several days or even weeks, proliferate, and are well characterised. Some of the major challenges of 
355 adapting these technologies to andrology come from the nature of human sperm cells. Sperm cells 
356 are highly specialised non-dividing cells, unique in shape and size with specialised organelles that do 
357 not actively transcribe or translate proteins. In practical terms, supply of cells is limited by donor or 
358 patient numbers and availability and cells cannot be cultured for long periods of time. Their 
359 preparation from raw semen is also limited to a time-consuming process that at least so far cannot 
360 be automated. Therefore, in all the assays described above, the sperm cells themselves are often the 
361 limiting factor, and this must be considered while planning their use in phenotypic screening, or with 
362 high-throughput technologies.
363 Conclusions
364 In conclusion we have discussed the potential advantages of using a newly available phenotypic 
365 screening platform for the human spermatozoa. Work is in its infancy, but it has the potential to 
366 facilitate the discovery of new areas of sperm biology to improve our understanding of this highly 
367 specialized cell type. Platform technologies such as this will help address key log jams in development 
368 of compounds to treat and conversely impair fertility (contraception), improve diagnostics assays and 
369 understanding. It will be exciting to see what new avenues this type of investigation bring to sperm 
370 biology. 
371
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386 Figure legends. 
387 Figure 1: The Flexibility of the high-throughput phenotypic screening platform and automation
388 The high-throughput sperm screening platform developed by Gruber et al. utilises a 384 well plate 
389 format and automation through liquid-handling machines and interchangeable measurement 
390 devices. Sperm cells from donor or patients can be observed within the system, and although the 
391 focus of platform development has been human sperm, the platform can also be used for the 
392 examination animal sperm such as bovine. Depending on the assay format, non-capacitating or 
393 capacitating conditions can be used and cells can be exposed to library compounds for defined 
394 periods of time, as well as controls and stains appropriate for each application. Interchangeable 
395 automated protocols and functional read-out devices can be used within the platform to allow assay 
396 flexibility. For each high-throughput application, complex automated, or semi-automated, data 
397 analysis is required to identify compounds with either positive or negative phenotypic effect. 
398 Identification. Identification of hit compounds is followed by further dose response confirmation.
399
400 Figure 2: Interchangeable assay modules can be used with the high-throughput platform
401 The phenotypic screening platform is designed to work with interchangeable read-out modules to 
402 allow multiple assays to be carried out on the same platform. The primary output of the platform 
403 discussed in this review is the sperm motility assay module (A), that consists of a microscopy-based 
404 readout followed by automated sperm tracking and analysis. This provides data on sperm numbers, 
405 motility, kinematics, hyperactivation and swimming patterns at multiple timepoints.
406 Further examples of other read-out modules and assays that can be achieved with the high-
407 throughput screening platform are illustrated, including a quantitative acrosome reaction, and 
408 sperm cell viability assays using flow cytometry (B), and intracellular calcium quantification using a 
409 spectrofluorometer (C). Furthermore, these read-out modules can be multiplexed together to gather 
410 additional information within the same automated cycle. For example, this could be a flow 
411 cytometry-based assay examining the acrosome reaction or cell viability in response to compounds 
412 that follow on from a motility read-out of the same cell population.
413
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Figure 1: The Flexibility of the high-throughput phenotypic screening platform and automation. 
The high-throughput sperm screening platform developed by Gruber et al. utilises a 384 well plate format 
and automation through liquid-handling machines and interchangeable measurement devices. Sperm cells 
from donor or patients can be observed within the system, and although the focus of platform development 
has been human sperm, the platform can also be used for the examination animal sperm such as bovine. 
Depending on the assay format, non-capacitating or capacitating conditions can be used and cells can be 
exposed to library compounds for defined periods of time, as well as controls and stains appropriate for each 
application. Interchangeable automated protocols and functional read-out devices can be used within the 
platform to allow assay flexibility. For each high-throughput application, complex automated, or semi-
automated, data analysis is required to identify compounds with either positive or negative phenotypic 
effect. Identification. Identification of hit compounds is followed by further dose response confirmation. 
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Figure 2: Interchangeable assay modules can be used with the high-throughput platform. 
The phenotypic screening platform is designed to work with interchangeable read-out modules to allow 
multiple assays to be carried out on the same platform. The primary output of the platform discussed in this 
review is the sperm motility assay module (A), that consists of a microscopy-based readout followed by 
automated sperm tracking and analysis. This provides data on sperm numbers, motility, kinematics, 
hyperactivation and swimming patterns at multiple timepoints. 
Further examples of other read-out modules and assays that can be achieved with the high-throughput 
screening platform are illustrated, including a quantitative acrosome reaction, and sperm cell viability assays 
using flow cytometry (B), and intracellular calcium quantification using a spectrofluorometer (C). 
Furthermore, these read-out modules can be multiplexed together to gather additional information within 
the same automated cycle. For example, this could be a flow cytometry-based assay examining the 
acrosome reaction or cell viability in response to compounds that follow on from a motility read-out of the 
same cell population. 
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